Table 3.
Summary of the similar studies on aflibercept treatment in resistant AMD cases
| Study group | No of eyes | Mean age | No of previous injections | No of Afl injections | Mean follow-up time (month) | Visual acuity (LogMAR) | CMT (micron) | ||
|---|---|---|---|---|---|---|---|---|---|
| Before Afl | After Afl | Before Afl | After Afl | ||||||
| Cho et al.1 | 28 | 80,68 (62-95) | 20,2±7,6 (7-37) | 4,4 (3-6) | 171 (134–192) days | 0,52 | 0,57 | 295 | 274 |
| Bakall et al.2 | 36 | 79 (60-88) | 25,6±(6-74) | 5,2 (4-6) | 6 | 0,45 | 0,50 | 410 (174-1027) | 296 (151-528) |
| Ho et al 3 | 96 | 79 (62-91) | 17 (1-60) | 2,6 (2-4) | 114 (90-133) days | 20/50 (snellen) | 0,02 (LogMAR) | 276 (130-559) | 258 (198-242) |
| Yonekawa et al 4 | 102 | 79,6 (57-93) | 20,4 (3-65) | 3,8 (1-8) | 18,4 weeks | 0,42 | 0,38 | 305,07 | 276,20 |
| Kumar et al 5 | 34 | 79 (72-84) | 28,6 (10-47) | 5,3 (5-6) | 6,5 (6-6,6) | 0,57 | 0,47 | 416±217 | 348±171 |
| Hall et al 6 | 30 | 80,4 (-) | 14,9 (2-53) | 6,27 (4-11) | 10,4 (3-12) | 0,533* | 0,521* | 264±12,5* | 237±10,2* |
| Heussen et al 7 | 71 | 77 (43-95) | 9 (3-43) | 2,7 (1-4) | - | 0,56+ | 0,43+ | 350.8±115+ | 260.8±34+ |
*values of 22 eyes with 12 moths follow-up period.
+values of 45 eyes which had 3 aflibercept injections.
Afl: Aflibercept, CMT: Central macular thickness.
1 Cho H, Shah CP, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 2013;97(8):1032-5.
2 Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156(1):15-22.
3 Ho VY, Yeh S,olsen TW, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor ınhibitors. Am J Ophthalmol. 2013;156(1):23-28.
4 Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156(1):29-35.
5 Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2012;33:1605–1612.
6 Hall LB, Zebardast N, Huang JJ and Adelman RA. Aflibercept in the treatment of neovascular age-related Macular degeneration in previously treated patients. J Ocul Pharmacol Ther. DOI: 10.1089/jop.2013.0188.
7 Heussen FM, Shao Q, Ouyang Y et al. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol DOI 10.1007/s00417-013-2553-7.